Analyst Price Targets — ABCL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 5, 2024 1:14 pm | Gary Nachman | BMO Capital | $5.00 | $2.74 | StreetInsider | AbCellera Biologics (ABCL) PT Lowered to $5 at BMO Capital |
| August 23, 2024 11:57 am | Scott Schoenhaus | KeyBanc | $5.00 | $2.60 | StreetInsider | KeyBanc Reiterates Overweight Rating on AbCellera Biologics (ABCL) |
| May 8, 2024 2:46 am | Scott Schoenhaus | KeyBanc | $7.00 | $3.84 | StreetInsider | AbCellera Biologics (ABCL) PT Lowered to $7 at KeyBanc |
| January 6, 2023 9:07 am | — | Leerink Partners | $18.00 | $9.63 | Benzinga | SVB Leerink Maintains Outperform on AbCellera Biologics, Lowers Price Target to $18 |
| December 15, 2022 4:41 am | Andrea Tan | Goldman Sachs | $30.00 | $10.13 | TheFly | AbCellera initiated with a Buy at Goldman Sachs |
| November 16, 2022 7:11 am | — | Truist Financial | $29.00 | $14.49 | Benzinga | Truist Securities Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $29 |
| August 10, 2022 8:56 am | — | Credit Suisse | $34.00 | $11.85 | Benzinga | Credit Suisse Maintains Outperform on AbCellera Biologics, Lowers Price Target to $34 |
Latest News for ABCL
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026.
AbCellera Biologics Inc. (ABCL) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript
AbCellera Biologics Inc. (ABCL) Presents at TD Cowen 46th Annual Health Care Conference Transcript
AbCellera Biologics (NASDAQ: ABCL) is positioning itself as a more pipeline-driven biotechnology company after more than a decade of platform investment, according to comments from Senior Director of Strategic Finance and Investor Relations Martin Hogan at TD Cowen's 46th Annual Health Care Conference. Hogan said AbCellera has spent "something like $1 billion" over roughly 13 years
AbCellera Biologics shares jumped 9.3% after hours to $3.52 following an 83% earnings beat in Q4 2025.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ABCL.
U.S. House Trading
No House trades found for ABCL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.